CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 415 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01844115
NCT01844115Phase 3Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.

Forest Laboratories·interventional·Posted May 1, 2013·Updated Dec 18, 2019

In Brief

A Phase 3 clinical trial evaluating Placebo and Vilazodone for Generalized Anxiety Disorder. Completed, enrolled 415 participants across 36 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 1, 2013
Enrollment StartApr 30, 2013
Primary CompletionMar 31, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.2 years ago

Interventions

Placebodrug

Vilazodonedrug

Viibryd